Dataset Information

Protocol to Generate and Characterize Potent and Selective WNT Mimetic Molecules.

ABSTRACT: WNT signaling is crucial for embryonic development, adult tissue homeostasis, and injury repair. The poor biophysical characteristics of WNTs and their lack of receptor selectivity have hindered their use as research tools or potential therapeutics. We have developed a platform to generate potent, soluble, selective WNT mimetics with drug-like properties for both research and therapeutic applications. To help researchers adapt and expand on this platform, we describe these protocols and key considerations in generating and studying WNT mimetics. For complete details on the use and execution of this protocol, please refer to Chen et al., 2020.

SUBMITTER: Chen H

PROVIDER: S-EPMC7580111 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Protocol to Generate and Characterize Potent and Selective WNT Mimetic Molecules.

Chen Hui H Lu Chenggang C Lee Sung-Jin SJ Li Yang Y

STAR protocols 20200603 1

WNT signaling is crucial for embryonic development, adult tissue homeostasis, and injury repair. The poor biophysical characteristics of WNTs and their lack of receptor selectivity have hindered their use as research tools or potential therapeutics. We have developed a platform to generate potent, soluble, selective WNT mimetics with drug-like properties for both research and therapeutic applications. To help researchers adapt and expand on this platform, we describe these protocols and key cons ...[more]

PMID: 33111090

Similar Datasets

Project description:Factor XIIIa (FXIIIa) is a cysteine transglutaminase that catalyzes the last step in the coagulation process. An anion-binding site inhibition of FXIIIa is a paradigm-shifting strategy that may offer key advantages of controlled inhibition. Such an approach is likely to lead to novel FXIIIa inhibitors that do not carry bleeding risks. We previously reported a flavonoid trimer-based allosteric inhibitor of FXIIIa with moderate potency and selectivity. To further advance this approach, we evaluated a series of 27 variably sulfonated heparin mimetics against human FXIIIa. Only 13 molecules exhibited inhibitory activity at the highest concentration tested with IC50 values of 2-286 μM. Specifically, inhibitor 16 demonstrated an IC50 value of 2.4 ± 0.5 μM in a bisubstrate, fluorescence-based trans-glutamination assay. It also demonstrated a significant selectivity over other clotting factors including thrombin, factor Xa, and factor XIa as well as other cysteine enzymes including papain and tissue transglutaminase 2. Inhibitor 16 did not affect the viability of three human cell lines at a concentration that is 5-fold its FXIIIa-IC50. The molecule had a very weak effect on the activated partial thromboplastin time of human plasma at a concentration of >700 μM, further supporting its functional selectivity. Importantly, molecule 16 inhibited FXIIIa-mediated polymerization of fibrin(ogen) in a concentration-dependent manner as shown by the gel electrophoresis experiment. Michaelis-Menten kinetics revealed that the molecule competes with the Gln-donor protein substrate, i.e., dimethylcasein, but not with the Lys-donor small substrate, i.e., dansylcadaverine. Molecular modeling studies revealed that this type of molecule likely binds to an anion-binding site comprising the basic amino acids of Lys54, Lys61, Lys73, Lys156, and Arg244 among others. Overall, our work puts forward a new anion-binding site, selective, nontoxic, sulfonated heparin mimetic FXIIIa inhibitor 16 for further development as an effective and safer anticoagulant.

Dataset Information

Protocol to Generate and Characterize Potent and Selective WNT Mimetic Molecules.

Publications

Protocol to Generate and Characterize Potent and Selective WNT Mimetic Molecules.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets